来索吡琼

**来索吡琼**
臨床資料
给药途径	口服给药
ATC碼	未分配;
法律規範狀態
法律規範	不受管制;
识别信息
	IUPAC命名法 2-{4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine; ;
CAS号	132449-46-8
PubChem CID	60813;
ChemSpider	54801;
UNII	H1CGM4755H;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID40157587 ;
化学信息
化学式	C15H21ClN6
摩尔质量	320.83 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES Clc1cn(nc1)CCCCN3CCN(c2ncccn2)CC3;

来索吡琼（INN：lesopitron；开发代号：E-4424）是5-HT_1A受体的选择性完全激动剂，其结构与阿扎匹隆相关。^[1]2001 年，Esteve将其开发作为抗焦虑药，用于治疗广泛性焦虑症。^[2]^[3]它进入了II期临床试验，但开发进度已停止，因为此后没有出现关于来索吡琼的新消息。^[2]^[3]

参见[编辑]

舒奈吡琼

参考资料[编辑]

^ Haj-Dahmane S, Jolas T, Laporte AM, et al. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat. European Journal of Pharmacology. April 1994, 255 (1–3): 185–96. PMID 8026543. doi:10.1016/0014-2999(94)90097-3.
^ ^2.0 ^2.1 Micheli F. Lesopitron (Esteve). IDrugs: The Investigational Drugs Journal. February 2001, 4 (2): 218–24. PMID 16032484.
^ ^3.0 ^3.1 Fresquet A, Sust M, Lloret A, et al. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. The Annals of Pharmacotherapy. February 2000, 34 (2): 147–53. PMID 10676820. doi:10.1345/aph.19041.

Template:Navbox with collapsible groups

[pmid8026543-1] Haj-Dahmane S, Jolas T, Laporte AM, et al. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat. European Journal of Pharmacology. April 1994, 255 (1–3): 185–96. PMID 8026543. doi:10.1016/0014-2999(94)90097-3.

[pmid16032484-2] 2.0 ^2.1 Micheli F. Lesopitron (Esteve). IDrugs: The Investigational Drugs Journal. February 2001, 4 (2): 218–24. PMID 16032484.

[pmid10676820-3] 3.0 ^3.1 Fresquet A, Sust M, Lloret A, et al. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. The Annals of Pharmacotherapy. February 2000, 34 (2): 147–53. PMID 10676820. doi:10.1345/aph.19041.

[1]

[2]

[3]